Online citations, reference lists, and bibliographies.
← Back to Search

Phase I And Pharmacokinetics Trial Of ABI-007, A Novel Nanoparticle Formulation Of Paclitaxel In Patients With Advanced Nonhematologic Malignancies.

D. Nyman, K. Campbell, E. Hersh, K. Long, K. Richardson, V. Trieu, N. Desai, M. Hawkins, D. V. Von Hoff
Published 2005 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
PURPOSE ABI-007 is a novel solvent-free, albumin-bound, 130-nm particle formulation of paclitaxel designed to avoid solvent-related toxicities and to deliver paclitaxel to tumors via molecular pathways involving an endothelial cell-surface albumin receptor (gp60) and an albumin-binding protein expressed by tumor cells and secreted into the tumor interstitium (secreted protein acid rich in cysteine). This study determined the maximum-tolerated dose (MTD) of ABI-007 monotherapy administered weekly (three weekly doses, repeated every 4 weeks) and assessed the pharmacokinetics of paclitaxel administered as ABI-007. PATIENTS AND METHODS Patients with advanced nonhematologic malignancies received ABI-007 without premedication at dose levels from 80 to 200 mg/m(2) as a 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest (one cycle). RESULTS Thirty-nine patients were treated with an average of five cycles of ABI-007; 33% of patients received > or = six cycles of treatment. MTDs for heavily and lightly pretreated patients were 100 and 150 mg/m(2), respectively; and the dose-limiting toxicities were grade 4 neutropenia and grade 3 peripheral neuropathy, respectively. Maximum paclitaxel concentration and area under the curve increased linearly with dose. Dose-dependent changes in plasma clearance did not occur. Partial responses were observed in five patients with breast, lung, and ovarian cancers, all of whom had previously been treated with paclitaxel containing polyoxyethylated castor oil in the formulation. CONCLUSION This study demonstrated that weekly ABI-007 can be administered at doses exceeding those typically used for paclitaxel containing polyoxyethylated castor oil. Pharmacokinetics were linear over the dose range studied. Antitumor responses occurred in patients previously treated with paclitaxel containing polyoxyethylated castor oil.
This paper references
10.1038/277665a0
Promotion of microtubule assembly in vitro by taxol
P. Schiff (1979)
10.1093/JNCI/82.15.1247
Taxol: a novel investigational antimicrotubule agent.
E. Rowinsky (1990)
10.1200/JCO.1990.8.7.1263
Hypersensitivity reactions from taxol.
R. Weiss (1990)
10.1016/0883-2897(92)90103-6
Design of compounds having enhanced tumour uptake, using serum albumin as a carrier--Part II. In vivo studies.
U. Schilling (1992)
10.1152/AJPHEART.1992.263.6.H1872
Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium.
J. Schnitzer (1992)
10.1177/43.8.7622842
Distribution of SPARC in normal and neoplastic human tissue.
P. Porter (1995)
10.1200/JCO.1996.14.6.1858
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
J. Nabholtz (1996)
10.1073/PNAS.93.1.250
Isolation and characterization of a cell surface albumin-binding protein from vascular endothelial cells.
C. Tiruppathì (1996)
10.1074/jbc.272.41.25968
Gp60 Activation Mediates Albumin Transcytosis in Endothelial Cells by Tyrosine Kinase-dependent Pathway*
C. Tiruppathì (1997)
10.1111/1523-1747.EP12334263
The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma.
F. Ledda (1997)
10.3346/JKMS.1998.13.6.652
Expression of osteopontin and osteonectin in breast cancer.
Y. Kim (1998)
10.1097/00005072-199812000-00002
SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas.
S. Rempel (1998)
10.1016/S0046-8177(99)90014-X
Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas.
D. Massi (1999)
10.1006/GYNO.1999.5552
Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer.
T. Brown (1999)
SPARC: a potential diagnostic marker of invasive meningiomas.
S. Rempel (1999)
Reversible ligand binding to human serum albumin. Theoretical and clinical aspects.
H. Vorum (1999)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.1006/GYNO.2000.5894
Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer.
P. Paley (2000)
10.1016/S0140-6736(00)02074-2
The taxanes: an update
J. Crown (2000)
Differential expression of osteonectin/SPARC during human prostate cancer progression.
R. Thomas (2000)
10.1200/JCO.2001.19.11.2937
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
A. Tolcher (2001)
10.1200/JCO.2001.19.22.4216
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.
E. Perez (2001)
10.1016/S0959-8049(01)00171-X
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
H. Gelderblom (2001)
10.1016/S0022-5347(05)65623-6
Analysis of the gene expression of SPARC and its prognostic value for bladder cancer.
M. Yamanaka (2001)
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
N. Ibrahim (2002)
10.2165/00003088-200342070-00005
Pharmacological Effects of Formulation Vehicles
A. J. Tije (2003)
10.1152/AJPLUNG.00242.2003
Caveolin regulation of endothelial function.
R. Minshall (2003)
10.1152/AJPLUNG.00152.2002
Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer.
T. A. John (2003)
10.1002/cncr.11368
Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression
K. Yamashita (2003)
10.1200/JCO.2003.09.081
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
M. Citron (2003)
10.1200/JCO.2004.08.048
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
E. Winer (2004)
10.1038/sj.bjc.6601303
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
J. Kloover (2004)
10.1158/1078-0432.CCR-04-2291
Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)
A. Sparreboom (2005)
10.1200/JCO.2005.11.013
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
N. Ibrahim (2005)
10.1200/JCO.2005.04.937
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)



This paper is referenced by
10.1002/9781119711698.CH15
Nanopharmaceuticals: An Approach for Effective Management of Breast Cancer
V. S. Belgamwar (2021)
10.1051/E3SCONF/202124503057
New Approved First-line Combining Therapy of NSCLC in 2020
Nianwu Wang (2021)
Role of Nanotechnology in Cancer Treatment
(2021)
10.1016/j.bioactmat.2021.02.037
Bioactive nanotherapeutic trends to combat triple negative breast cancer
P. Chowdhury (2021)
10.3390/cancers12061404
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
J. S. Lee (2020)
10.2217/fon-2019-0742
Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients.
A. Fabi (2020)
10.1002/cpdd.803
Population Pharmacokinetics and Exposure‐Response Analysis of nab‐Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors
Y. Li (2020)
10.1177/1559325820936161
Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology
Lina Yan (2020)
10.1055/a-1126-4247
Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
O. Gluz (2020)
10.1016/j.biomaterials.2020.120357
Nanocomposite hydrogel with NIR/magnet/enzyme multiple responsiveness to accurately manipulate local drugs for on-demand tumor therapy.
Pingyun Yuan (2020)
10.1038/s41598-020-76465-9
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
G. Roviello (2020)
10.22270/jddt.v10i3.3979
Formulation and Evaluation of Protein Bound Paclitaxel Nanoparticles for Injectable Suspension
S. Jain (2020)
10.1038/s42003-020-01294-5
Transferrin receptor 1 is a cellular receptor for human heme-albumin
Brell Jennifer (2020)
10.1007/978-981-15-4802-4_7
Application of Nanomaterials in the Diagnosis and Treatment of Genetic Disorders
Alaa A A Aljabali (2020)
10.2174/1573413715666190206151757
Nanoparticle-assisted Therapeutic Strategies for Effective Cancer Management
D. Nandi (2020)
10.1080/14656566.2019.1569628
Efficacy of nab-paclitaxel in treating metastatic melanoma
P. Specenier (2019)
10.1007/s00280-019-03887-2
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer
G. Roviello (2019)
10.1080/14656566.2018.1546290
Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence
D. A. Adrianzen Herrera (2019)
10.1016/j.jfma.2019.01.015
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.
Shih-Hung Yang (2019)
10.1177/2050312119836011
Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System
Misa Naganuma (2019)
10.1177/1533033819879902
Organic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myeloid Leukemia
Mohammed Hussein Kamareddine (2019)
10.1016/j.semcancer.2019.10.020
Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges.
Z. Mirza (2019)
10.1007/s12325-019-00909-6
Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
O. Borgå (2019)
Carcinoma of Unknown Primary Site: A Mini-Review on Chemotherapy and the Expectation for Treatment with Nab-Paclitaxel Plus Carboplatin
Y. Ichikawa (2019)
10.2147/CMAR.S208224
A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
M. Tachihara (2019)
CMAR_A_208224 7135..7140
M. Tachihara (2019)
10.1007/s00280-019-03843-0
A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer
Y. Kato (2019)
10.21518/2079-701X-2018-19-56-60
Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
E. Borisova (2018)
10.1021/acs.molpharmaceut.8b00527
Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.
F. Li (2018)
10.2147/IJN.S169209
Pure paclitaxel nanoparticles: preparation, characterization, and antitumor effect for human liver cancer SMMC-7721 cells
Chao Wu (2018)
10.1007/s00775-018-1600-6
Potential applications of engineered nanoparticles in medicine and biology: an update
G. R. Rudramurthy (2018)
10.1016/B978-0-323-35955-9.00069-6
Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer
Adrienne G Waks (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar